At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21 enrolled
Drug / intervention
Deuterium metabolic imagingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MRI Assessment of Impaired Glucose Metabolism in Alzheimer's Disease
In Brief
An observational study evaluating Deuterium metabolic imaging for Alzheimer Disease. Completed, enrolled 21 participants across 1 site.
Detailed Summary
Diseases of dementia are chronic, untreatable, and cause a massive burden of morbidity. In this proposal, we seek to tackle the problem of better, earlier, and more efficient diagnosis using deuterium metabolic imaging (DMI). The study is divided in two sub-studies: 1) optimization and simplification of DMI protocols, and 2) a cross-sectional study of DMI in Alzheimer's patients and healthy controls.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesDenmark
CollaboratorsAarhus University Hospital
Timeline
N/ACompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartDec 2022
Primary CompletionOct 2023
TodayJul 2026
First PostedJun 2, 2022
Enrollment StartDec 22, 2022
Primary CompletionOct 27, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.1 years ago
Interventions
Deuterium metabolic imagingother
MRI after oral administration of 75g of \[6,6'-2H2\]glucose.